The fear everyone has
A lot of people assume: stop Ozempic/Wegovy/Mounjaro/Zepbound → regain everything. Earlier randomized trials showed substantial regain after stopping, which fueled that worry.
What the real-world data found
A Cleveland Clinic team examined 7,938 adults in Ohio and Florida who started injectable semaglutide or tirzepatide (for obesity/overweight or type 2 diabetes) and then stopped within 3–12 months.
One year after stopping:
- People treated for obesity regained ~0.5% on average after losing ~8.4% before stopping.
- People treated for type 2 diabetes lost an additional ~1.3% on average after stopping.
- But variability was huge: in the obesity group, 55% gained, while 45% maintained or kept losing.
The “off-ramp” playbook
Many patients didn’t just stop and hope for the best. Within 12 months:
- 27% switched to another medication
- 20% restarted the original medication
- 14% continued with lifestyle-focused visits (dietitians/exercise specialists)
So the real-world story is often: stop → adjust → continue the plan.
Who tended to regain vs maintain
If you ever change or stop a tool (meds, meal plan, routine), the win is having a “next step” ready:
- Pick one anchor habit (protein at breakfast, 10-min walk after lunch, 3 strength sessions/week).
- Add structure before motivation fades (a schedule beats willpower).
- If appetite rebounds, treat it as signal, not failure—adjust food environment and stress/sleep first.
The gentle reality check
This was observational EHR data, not a randomized trial, and it reflects how people behave in real clinics (switching/restarting/support). It’s encouraging—but it’s not a guarantee for any individual.
